-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Spero Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2019 to Q2 2024.
- Spero Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $1.2M, a 22.8% increase year-over-year.
- Spero Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.5M, a 52.8% increase year-over-year.
- Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $3.92M.
- Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.22M, a 136% decline from 2021.
- Spero Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.79M, a 314% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)